Next Article in Journal
Medication Trials for Hyperphagia and Food-Related Behaviors in Prader–Willi Syndrome
Next Article in Special Issue
Menahydroquinone-4 Prodrug: A Promising Candidate Anti-Hepatocellular Carcinoma Agent
Previous Article in Journal
Growth Hormone Therapy in Adults with Prader-Willi Syndrome
Previous Article in Special Issue
A Role for Acyclic Retinoid in the Chemoprevention of Hepatocellular Carcinoma: Therapeutic Strategy Targeting Phosphorylated Retinoid X Receptor-α
Open AccessArticle

Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

Department of Internal Medicine, Hepatology Division, Saga University Hospital, 5-1-1 Nabeshima, Saga 849-8501, Japan
Department of Internal Medicine, Saiseikai Karatsu Hospital, 817 Motohata-machi, Karatsu 847-0852, Japan
Department of Internal Medicine, Gastroenterology Division, NHO Ureshino Medical Center, 2436 Shimojuku-hei Ureshino-machi, Ureshino 843-0393, Japan
Department of Internal Medicine, Karatsu Red Cross Hospital, 1-5-1 Futago, Karatsu 847-8588, Japan
Department of Hepatobiliary and Pancreatology, Saga-Ken Medical Centre Koseikan, 400 Nakabaru, Kase-machi, Saga 840-8571, Japan
Liver center, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
Author to whom correspondence should be addressed.
Members of the Saga Liver Cancer Study Group. The Saga Liver Cancer Study Group is composed of tertiary-care hospitals with specialists in liver cancer treatment in Saga Prefecture, Japan.
Academic Editor: Stephen L. Chan
Diseases 2015, 3(2), 68-77;
Received: 26 March 2015 / Revised: 19 April 2015 / Accepted: 6 May 2015 / Published: 15 May 2015
(This article belongs to the Special Issue Targeted Therapy of Hepatocellular Carcinoma: Present and Future)
Sorafenib exerts modest antitumor activity in patients with advanced hepatocellular carcinoma (HCC), and radiological progressive disease (rPD) does not always correspond to so-called clinical progressive disease (cPD). We evaluated 101 patients who initiated sorafenib treatment for HCC and assessed post-progression survival (PPS) using the Cox proportional hazards model. PPS was calculated from the date of the first rPD until the date of death or the last follow-up. Using Cox model analysis of the 76 patients who experienced first rPD, we identified the Child-Pugh class, Eastern Cooperative Oncology Group performance status, the best antitumor response during treatment (using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1) and α-fetoprotein levels as independent factors affecting PPS. When these factors were used to define scores ranging from zero to five with a cutoff value of two, PPS of patients who received best supportive care (BSC) after rPD was not statistically significantly different from that of patients who received post-rPD therapy with scores ≥2 (p = 0.220). In contrast, the PPS for the post-rPD therapy group was significantly longer compared with the BSC patients with scores <2 (p < 0.001). Patients who scored ≥2 at their first rPD were judged cPD and as candidates for BSC. View Full-Text
Keywords: beyond progression; progressive disease; scoring system; post-progression survival beyond progression; progressive disease; scoring system; post-progression survival
Show Figures

Figure 1

MDPI and ACS Style

Otsuka, T.; Nakashita, S.; Yanagita, K.; Ario, K.; Kawasoe, H.; Kawazoe, S.; Eguchi, Y.; Mizuta, T. Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Diseases 2015, 3, 68-77.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop